Adcendo

Innovative ADCs to treat cancer

Series C+
Copenhagen, Denmark
Founded 2017
Website

About

Founded in Copenhagen, Denmark, Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. The company focuses on creating best-in-class clinical ADC candidates by combining proprietary linker and payload technologies designed to improve efficacy and safety. Adcendo operates as a clinical-stage biotech firm, advancing its ADC pipeline through strategic clinical trials and collaborations, funded by multiple rounds including a recent oversubscribed $75M Series C funding round to accelerate development and commercialization.

Products

  • ADCE-T02 — Tissue Factor-targeting antibody-drug conjugate for treating advanced solid tumors, designed to enhance anti-tumor activity.
    Customer sectors: oncology researchers, pharmaceutical developers, clinical trial investigators

Company Details

Sector Deep Tech
Category Biotech & Therapeutics
Stage Series C+
Total Funding $75.0M
Employees 51-200
Last Funded April 14, 2026
Last Round $75.0M

Market research & competitive positioning

Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Adcendo — available to members.

Create a free account Sign in